Cover Image
市場調查報告書

全球照護現場(POC)診斷市場未來展望

Global Point-of-Care Diagnostics Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 304704
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
全球照護現場(POC)診斷市場未來展望 Global Point-of-Care Diagnostics Market Outlook 2020
出版日期: 2015年05月01日 內容資訊: 英文 75 Pages
簡介

所謂照護現場(Point of Care:以下POC)檢查,是患者在開業醫院和救護車、家中、室外、醫院等各種地方可接受診斷的檢查技術。在現場能得到檢驗結果,可進行急救治療,使醫療服務大幅度改善。隨著各種技術(微射流、數位光學技術、實驗室晶片等)的開發、改良,全球的POC檢驗(POCT)市場預計2020年達到300億美元的規模。美國佔市場45%,接下來依次為歐洲、日本。已開發國家的可攜式的檢查裝置開發、文明病的患病人數增加等促進市場成長,另一方面,就算資源的規定有嚴格之處也可診斷的特徵,也促進新興國家的市場。

本報告提供全球的照護現場(POC)診斷的相關市場相關分析、技術概要和今後的技術開發預測、全球各地區、主要國家今後的市場機會、主要企業簡介的資訊,為您概述為以下內容。

第1章 分析師的見解

第2章 分析方法

第3章 體外診斷市場概要

  • 簡介
  • 體外(IV)診斷是什麼?
  • 市場規模與成長率

第4章 POC(照護現場)診斷市場未來展望

第5章 市場區隔

  • 各應用領域
  • 各地區

第6章 市場成長的促進要素及課題

  • 促進成長要素
  • 課題

第7章 產業的趨勢與發展

  • 可攜式超音波設備在醫療現場活躍
  • 湧來POCT產業的微流體工程技術

第8章 競爭環境

  • 大企業的市場佔有率
  • 主要企業
    • Roche Holding Ltd.
    • Abbott Laboratories
    • Johnson and Johnson
    • Alere
    • Medtronic
    • Bayer HealthCare
    • Siemens HealthCare
    • Beckman Coulter
    • Bio-Rad
    • Becton Dickinson

第9章 未來展望與市場機會

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

It is widely accepted that disease prevention and risk-reduction strategies have the potential to lower disease burden as well as improve the overall health of individuals. POCT technology offers such potential for diagnosis and treatment of patients, as it facilitates rapid availability of test results and hence, early clinical decision making and intervention.

Amidst a rising disease incidence, reduced budget, growing focus towards personalization of care, and ever-increasing integration of technology into healthcare, the global POCT market is expected to grow to almost US$ 30 Billion by 2020. In the "Global Point-of-Care Diagnostics Market Outlook 2020" report, the global POCT industry has been shown at a very crucial stage with POCT expanding into diverse disease areas, such as cancer and HIV diagnostics. The coming years will witness POCT take over routine diagnostics as focus would shift from 'curative' onto 'preventive care with enhanced patient involvement.'

Currently, the United States accounts for almost 45% of the total POCT market, followed by regions, such as Europe and Japan. In these developed regions, the proliferation of transportable, portable and handheld instruments along with ever-increasing incidence of lifestyle related disorders, such as diabetes has supported the growth of Point of Care testing. At the same time, rapid advancements in technology and infrastructure and the availability of diagnostic systems that cannot be employed in resource limited settings is expected to result in enhanced uptake of POCT in emerging nations. Countries such as Japan, China, India, Brazil and Mexico are expected to evolve as hot spots for development of the POCT technology in future.

The report provides a brief outlook of the IVD industry, covering major aspects, such as current market size, future growth, and current and future geographical segmentation. It also talks about the major players of IVD industry and their respective contribution to the current market.

The report then moves on to the global POCT industry, its current market size and future forecasts. Markets for major application segments such as glucose testing, blood chemistry etc. have also been discussed. Trends such as advanced micro fluidics, lab-on-a-chip assays as well as portable technologies have been elaborated. At the end, major players of the industry have been highlighted and a thorough profiling has been carried out to present the POCT product portfolios, business segmentations, strengths and weakness, and recent developments of every player.

Table of Contents

1. Analyst View

2. Research Methodology

3. In Vitro Diagnostic Market Overview

  • 3.1 Introduction
  • 3.2 What is In Vitro Diagnostics?
  • 3.3 Market Size and Growth

4. Point-of-Care Diagnostics Market Outlook 2020

5. Market Segmentation

  • 5.1 By Application
  • 5.2 By Geography

6. Market Drivers and Challenges

  • 6.1 Drivers
  • 6.2 Challenges

7. Industry Trends and Developments

  • 7.1 Portable Ultrasound Providing Care on Site
  • 7.2 Microfluidics Technology Crowding the POCT Industry

8. Competitive Landscape

  • 8.1 Market Share of Major Players
  • 8.2 Key Players
    • 8.2.1 Roche Holding Ltd.
    • 8.2.2 Abbott Laboratories
    • 8.2.3 Johnson and Johnson
    • 8.2.4 Alere
    • 8.2.5 Medtronic
    • 8.2.6 Bayer HealthCare
    • 8.2.7 Siemens HealthCare
    • 8.2.8 Beckman Coulter
    • 8.2.9 Bio-Rad
    • 8.2.10 Becton Dickinson

9. Future Outlook/Market Opportunities

List of Figures:

  • Figure 3-1: Global - Diabetes Incidence (Million), 2014 & 2035
  • Figure 3-2: Global - In Vitro Diagnostic Market (Billion US$), 2014-2020
  • Figure 3-3: Global - In Vitro Diagnostic Market by Region (%), 2014
  • Figure 3-4: Global - In Vitro Diagnostic Market by Region (%), 2020
  • Figure 3-5: Global - In Vitro Diagnostic Market by Players (%), 2014
  • Figure 4-1: Global - Share of POCT in the IVD Market (%), 2014 & 2020
  • Figure 4-2: Global - Point of Care Testing Market (Billion US$), 2014-2020
  • Figure 5-1: Global - Point of Care Testing Market by Application (%), 2014
  • Figure 5-2: Global - Point of Care Testing Market by Application (%), 2020
  • Figure 5-3: Global - Point of Care Testing Market by Players (%), 2014
  • Figure 8-1: Global - Point-of-Care Testing Market by Players (%), 2014
  • Figure 8-2: Roche Holdings Ltd - Revenue by Business Segment (%), 2014
  • Figure 8-3: Abbott Laboratories - Revenue by Business Segment (%), 2014
  • Figure 8-4: Abbott Laboratories - Revenue by Region (%), 2014
  • Figure 8-5: Johnson & Johnson - Revenue by Business Segment (%), 2014
  • Figure 8-6: Johnson & Johnson - Medical Devices and Dx Revenue by Segment (%), 2014
  • Figure 8-7: Johnson & Johnson - Revenue by Region (%), 2014
  • Figure 8-8: Johnson & Johnson - Medical Devices and Dx Revenue by Region (%), 2014
  • Figure 8-9: Alere Inc. - Revenue by Business Segment (%), 2013
  • Figure 8-10: Alere Inc. - Professional Diagnostic Division Revenue by Segment (%), 2013
  • Figure 8-11: Medtronic Inc. - Revenue by Business Segment (%), 2014
  • Figure 8-12: Medtronic Inc. - Revenue by Region (%), 2014
  • Figure 8-13: Bayer HealthCare - Revenue by Business Segment (%), 2014
  • Figure 8-14: Bayer HealthCare - Revenue by Business Region (%), 2014
  • Figure 8-15: Bayer HealthCare - Consumer Health Revenue by Segment (%), 2014
  • Figure 8-16: Siemens HealthCare - Revenue by Region (%), 2014
  • Figure 8-17: Siemens HealthCare - Revenue by Business Segment (%), 2014
  • Figure 8-18: Bio-Rad - Revenue by Segment (%), 2014
  • Figure 8-19: Bio-Rad - Revenue by Region (%), 2014
  • Figure 8-20: Becton Dickinson - Revenue by Business Segment (%), 2014
  • Figure 8-21: Becton Dickinson - Revenue by Region (%), 2014

List of Tables:

  • Table 8-1: Roche Holdings Ltd - POCT Product Portfolio
  • Table 8-2: Roche Holdings Ltd - Key POCT Product Launches for 2015
  • Table 8-3: Roche Holdings Ltd - Key Financials (Million CHF), 2012-2014
  • Table 8-4: Roche Holdings Ltd - Strengths and Weaknesses
  • Table 8-5: Abbott Laboratories - POCT Product Portfolio
  • Table 8-6: Abbott Laboratories - Key Financials (Million US$), 2012-2014
  • Table 8-7: Abbott Laboratories - Strengths and Weaknesses
  • Table 8-8: Johnson & Johnson - POCT Product Portfolio
  • Table 8-9: Johnson & Johnson - Key Financials (Million US$), 2012-2014
  • Table 8-10: Johnson & Johnson - Strengths and Weaknesses
  • Table 8-11: Alere Inc. - POCT Product Portfolio
  • Table 8-12: Alere Inc. - Key Financials (Million US$), 2011-2013
  • Table 8-13: Alere Inc. - Strengths and Weaknesses
  • Table 8-14: Medtronic Inc. - POCT Product Portfolio
  • Table 8-15: Medtronic Inc. - Key Financials (Million US$), 2012-2014
  • Table 8-16: Medtronic Inc. - Strengths and Weaknesses
  • Table 8-17: Bayer HealthCare - POCT Product Portfolio
  • Table 8-18: Bayer HealthCare - Key Financials (Million €), 2012-2014
  • Table 8-19: Bayer HealthCare - Strengths and Weaknesses
  • Table 8-20: Siemens Healthcare - POCT Product Portfolio
  • Table 8-21: Siemens Healthcare - Key Financials (Million €), 2012-2014
  • Table 8-22: Siemens Healthcare - Strength and Weaknesses
  • Table 8-23: Beckman Coulter - POCT Product Portfolio
  • Table 8-24: Beckman Coulter - Strengths and Weaknesses
  • Table 8-25: Bio-Rad - POCT Product Portfolio
  • Table 8-26: Bio-Rad - Key Financials (Million US$) 2012-2014
  • Table 8-27: Bio-Rad - Strengths and Weaknesses
  • Table 8-28: Becton Dickinson - POCT Product Portfolio
  • Table 8-29: Becton Dickinson - Key Financials (Million US$), 2012-2014
  • Table 8-30: Becton Dickinson - Strengths and Weaknesses
Back to Top